Latest news for Biophytis (OTC:BPTSY) Stock

Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate BIO101, is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.

Biophytis SA

News

Boeing And Antonov To Collaborate On Defense Projects; Signed MOU To Work With Ukrainian Industry

Coca-Cola Consolidated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) has outperformed the market over the past 15 years by 9.41% on an annualized basis producing an average annual return of 21.63%. Currently, Coca-Cola Consolidated has a market capitalization of $9.51 billion. 
Buying $1000 In COKE: If an investor had bought $1000 of COKE stock 15 years ago, it would be worth $19,095.43 today based on a price of $1085.50 for COKE at the time of writing.
<h3>Coca-Cola Consolidated's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721665816_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

COKE

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $19,000 Today

Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) has outperformed the market over the past 20 years by 7.72% on an annualized basis producing an average annual return of 16.09%. Currently, Cheniere Energy has a market capitalization of $41.28 billion. 
Buying $1000 In LNG: If an investor had bought $1000 of LNG stock 20 years ago, it would be worth $20,063.40 today based on a price of $180.35 for LNG at the time of writing.
<h3>Cheniere Energy's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721665811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Cheniere Energy 20 Years Ago Would Be Worth This Much Today

Former President <a href="https://finance.yahoo.com/news/heres-much-profit-donald-trump-121454764.html">Donald Trump</a> has set the bar high for his upcoming fundraiser at the Bitcoin 2024 Conference in Nashville. The invitation for his exclusive event, scheduled for July 27, boasts an astonishing $844,600 ticket price. According to Bloomberg, this is the " … maximum combined campaign contribution to the Trump campaign and the Republican National Committee that's allowed under campaign finance laws." This is equivalent to around 13 <a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment/">Bitcoin (BTC)</a> in today's market. However, the event&#8217;s high cost is not the only headline, as the <a href="https://finance.yahoo.com/news/kevin-oleary-says-assassination-attempt-141514067.html">recent assassination of Trump</a> has introduced a sense of unease among attendees.
Don't /miss:
<ul>
<li>1 in 4 Americans own a share of Bitcoin according to NASDAQ,<a href="https://www.benzinga.com/money/nasdaq-1in4-adv"> how many people got started through this free crypto faucet?</a></li>
<li><a href="https://www.benzinga.com/money/plus500">Want to trade futures? Discover why 25 million chose this Chicago Bulls sponsor.</a></li>
</ul>
This event aims to raise funds for Trump's presidential campaign while showcasing his newfound enthusiasm for crypto. Years prior, he dismissed Bitcoin as a "scam," but he has since departed from his skepticism. Trump's recent speeches illustrate his determination to protect and enhance Bitcoin and the rest of crypto, coining him the "crypto president." Specifically, Trump pledged to keep Sen. Elizabeth Warren and "her goons" away from Bitcoin holders.
Attendees paying for the near million-dollar ticket will receive roundtable seating, a photo with Trump, and VIP access to the reception. The invitation also mentions a photo opportunity with Trump for $60k per person and $100k per couple. Trump is expected to be the lead voice for the conference with guest speakers including Ohio Sen. JD Vance (Trump's newly elected running mate), Vivek Ramaswamy (Trump&#8217;s primary Republican opponent) and <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38517674/cathie-wood-raises-her-bitcoin-prediction-by-2-3-million-what-1-000-invested-could-be-wort">Cathie Wood (Ark Invest's CEO)</a>.&nbsp;
According to the invitation&#8217;s email, the organizers have capped the event&#8217;s attendance at an estimated 100-150 donors, who &#8220;will enjoy drinks and hors d&#8217;oeuvres while mingling with influential guests.&#8221; If fully booked, the event is estimated to bring in $130 million.
Trending: If you invested $100 in DOGE when Elon Musk first tweeted about it in 2019,<a href="https://www.benzinga.com/money/bydfi-doge"> here&#8217;s how much you&#8217;d have today</a>.
With the event centered around digital currency, there are rumors about accepting crypto as a payment method. According to Decrypt, the attendees can purchase tickets using crypto via Coinbase, Gemini, or Anedot. The ongoing acceptance of crypto hints at the likelihood of digital asset integration for future political fundraising.&nbsp;
Trump's fundraiser coinciding with Bitcoin 2024 is more than an expensive event. It's a calculated move that facilitates his political and financial influence. Trump seems to be aiming to capitalize on a new wave of supporters by offering a fresh perspective on the future of finance. This strategy could prove pivotal in his campaign and set the tone for future elections.&nbsp;
However, not everyone is fond of Trump's unique initiatives. Trump's new crypto advocacy has come with significant criticism. Many of his traditional supporters view his shift with suspicion. Critics argue that his new stance contradicts previous statements and neglects attention from traditional finances. Many financial experts have voiced concerns over volatility and regulatory challenges that come with crypto.&nbsp;
Overall, Trump's fundraiser at Bitcoin 2024 represents a distinctive move that strengthens ties with crypto while potentially losing the interest of others. Whether or not this strategy will wind up victorious remains unknown, but one thing is certain: Trump is attempting to reconstruct America&#8217;s financial and political landscape.&nbsp;
Read Next:
<ul>
<li>General Motors and other leaders revealed to be<a href="https://www.benzinga.com/money/energyx"> investing in this revolutionary lithium start-up — allowing easy entry by launching at just $9.50 per share.</a></li>
<li>America's construction sites are desperate for Robots —<a href="https://www.benzinga.com/money/apis-cor"> here&#8217;s how to invest in a house-printing startup who&#8217;s making them and be a part of a $16 trillion industry</a>.</li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Trump Fundraiser At Bitcoin Conference Reaches $845K Asking Price Per Seat

Allarity Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) revealed on Monday it received a &#8220;Wells Notice&#8221; from the U.S. <a href="https://www.benzinga.com/pressreleases/24/07/g39878827/allarity-therapeutics-outlines-companys-2024-progress-and-objectives" target="_blank" rel="noreferrer noopener">Securities and Exchange Commission (SEC)</a>.
This notice pertains to the company&#8217;s disclosures about meetings with the Federal Drug Administration (FDA) regarding their New Drug Application (NDA) for Dovitinib or Dovitinib-DRP, submitted in 2021.
In December 2021, Allarity Therapeutics submitted a marketing application to the FDA seeking approval for dovitinib for the third-line treatment of <a href="https://www.benzinga.com/general/biotech/21/12/24738868/whats-happening-with-allarity-therapeutics-stock-today" target="_blank" rel="noreferrer noopener">renal cell carcinoma (RCC) patients</a>.  
The company&#8217;s NDA filing was supported by its prior pre-market approval (PMA) submission with the FDA for using Dovitinib-DRP, its companion diagnostic for the drug, to select and treat RCC patients most likely to respond to dovitinib.
Additionally, three former officers of Allarity have received similar notices from the SEC related to this issue.
A Wells Notice indicates the SEC staff made a preliminary determination to recommend enforcement action, alleging violations of federal securities laws.
It is not a formal charge but suggests potential legal action.
Allarity disclosed that all conduct related to the SEC&#8217;s notice occurred during or before the fiscal year 2022.
The company remains cooperative with the SEC and plans to submit a formal response, asserting its actions were appropriate.
Allarity&#8217;s board of directors has proposed a reverse stock split to shareholders to regain and sustain compliance with NASDAQ&#8217;s listing requirements.
The company said it will focus on advancing stenoparib, a novel dual PARP and Tankyrase inhibitor.
Recently, Allarity Therapeutics announced the early discontinuation of its Phase 2 clinical trial of stenoparib for advanced&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38591401/why-is-nano-cap-allarity-therapeutics-stock-trading-up-on-thursday" rel="noreferrer noopener">recurrent ovarian cancer</a>.&nbsp;
The trial, evaluating stenoparib given twice daily, showed clear clinical benefits, including tumor shrinkage and long-term disease stability, in heavily pretreated ovarian cancer patients.&nbsp;
Allarity Therapeutics announced the company has a financial runway extending into 2026 at its current burn rate with a cash balance of $20 million.
The company also plans to pause its ATM offering program for the foreseeable future.
ALLR Price Action: Allarity stock is down 8.33% at 15 cents at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39885749/nano-cap-mira-pharmaceuticals-oral-ketamine-analog-shows-potential-in-neuropsychiatric-disorders" target="_blank" rel="noreferrer noopener">Nano-Cap MIRA Pharmaceuticals&#8217; Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders</a>.</li>
</ul>

Biotech

Government

Penny Stocks

Health Care

Legal

General

ALLR

Allarity Therapeutics Hit By SEC Notice Related Disclosures Of Once Lead Cancer Program

Evercore ISI Group analyst James West maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Outperform and raises the price target from $73 to $74.

Price Target

Analyst Ratings

Evercore ISI Group Maintains Outperform on Schlumberger, Raises Price Target to $74

Evercore ISI Group analyst James West maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Outperform and lowers the price target from $52 to $48.

Evercore ISI Group Maintains Outperform on Halliburton, Lowers Price Target to $48

Citigroup analyst Joao Pedro Soares maintains Despegar.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) with a Neutral and raises the price target from $14.5 to $15.

DESP

Citigroup Maintains Neutral on Despegar.com, Raises Price Target to $15

In the wake of President Joe Biden&#8217;s decision to withdraw from the <a href="https://www.benzinga.com/news/24/07/39874154/bidens-exit-from-presidential-race-sparks-massive-reactions-from-first-lady-gavin-newsom-marjorie-ta">race for the presidency</a>, a Kamala Harris-themed meme coin, Kamala Horris (CRYPTO: KAMA), has hit a new all-time high.
What Happened: KAMA peaked at a high of over $30 million after Biden&#8217;s announcement, a more than 1,500% return since the start of the month. The meme coin is currently trading around a valuation of $16 million, ahead of the Biden-themed Jeo Boden (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BODEN</a>) at $6 million. BODEN has lost over 99% of its value from the peak.
Politics-themed tokens oscillate in value according to news of the candidates they represent. Notably, BODEN peaked in March after Joe Biden delivered a <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37568099/how-bidens-state-of-the-union-affects-2024-white-house-odds">State of the Union address</a>, which was well received.
The shift in value from BODEN to KAMA indicates the market&#8217;s response to Biden&#8217;s withdrawal and the subsequent endorsement of Harris.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/news/24/07/39875041/gavin-newsom-backs-kamala-harris-calls-vp-tough-fearless-and-tenacious-the-ideal-candidate-to-counte">Gavin Newsom Backs Kamala Harris, Calls VP Tough, Fearless And Tenacious: &#8216;The Ideal Candidate To Counter Donald Trump&#8217;</a>
Why It Matters: Political meme coins have seen a surge in activity, with traders creating new tokens in response to the changing political landscape. 
Even before Kamala Harris officially announced to run for the presidency, crypto traders had predicted upside for the KAMA meme coin.
One trader forecasted that "Kamala becomes the candidate this sends hard, worth a gamble."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">There is just no way they let Biden be the candidate for the election. Kamala seems like the obvious replacement<a href="https://twitter.com/search?q=%24KAMA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$KAMA</a> on SOL is a clear buy at $8M MC, <a href="https://twitter.com/search?q=%24BODEN&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BODEN</a> hit $650M 3 months back IF Kamala becomes the candidate this sends hard, worth a gamble! <a href="https://t.co/UI0D4JLXLm">https://t.co/UI0D4JLXLm</a> <a href="https://t.co/4i9SzQDm53">pic.twitter.com/4i9SzQDm53</a>
&mdash; Crypto Hype (@CryptoHypeReal) <a href="https://twitter.com/CryptoHypeReal/status/1812115130143953348?ref_src=twsrc%5Etfw">July 13, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Venture Coinist Luke Martin <a href="https://x.com/VentureCoinist/status/1808504187627483245">added</a> on July 3 that KAMA still needed a 100% gain to overtake BODEN, saying, "This is either the dumbest trade or the easiest 2x in crypto. Or both."
What&#8217;s Next: The influence of meme coins and <a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a> is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39874401/betting-markets-favor-kamala-harris-as-top-democratic-presidential-contender">Betting Markets Favor Kamala Harris As Top Democratic Presidential Contender</a></li>
</ul>
Image: Shutterstock

$BODEN

Kamala Harris-Inspired KAMA Meme Coin Explodes 1,500% In 3 Weeks, Flips Biden-Themed BODEN Coin

Evercore ISI Group analyst Chris McNally maintains Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) with a Outperform and lowers the price target from $150 to $140.

Evercore ISI Group Maintains Outperform on Autoliv, Lowers Price Target to $140

TD Cowen analyst John Kernan maintains Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) with a Buy and raises the price target from $77 to $79.

TD Cowen Maintains Buy on Skechers USA, Raises Price Target to $79

Citigroup analyst Jon Tower maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Neutral and lowers the price target from $85 to $80.

SBUX

Citigroup Maintains Neutral on Starbucks, Lowers Price Target to $80

Baird analyst Mircea Dobre maintains Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) with a Neutral and raises the price target from $58 to $67.

Baird Maintains Neutral on Terex, Raises Price Target to $67

TD Cowen analyst Marc Bianchi maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Buy and lowers the price target from $47 to $45.

TD Cowen Maintains Buy on Halliburton, Lowers Price Target to $45

Citigroup analyst Itay Michaeli maintains Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) with a Neutral and lowers the price target from $119 to $108.

Citigroup Maintains Neutral on Autoliv, Lowers Price Target to $108

Truist Securities analyst Joon Lee maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Buy and raises the price target from $480 to $540.

ARGX

Truist Securities Maintains Buy on argenx, Raises Price Target to $540

TD Cowen analyst Marc Bianchi maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Buy and raises the price target from $62 to $64.

TD Cowen Maintains Buy on Schlumberger, Raises Price Target to $64

Citigroup analyst Keith Horowitz maintains State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) with a Neutral and raises the price target from $85 to $90.

Citigroup Maintains Neutral on State Street, Raises Price Target to $90

Truist Securities analyst Brandon King maintains Wintrust Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>) with a Buy and raises the price target from $107 to $118.

WTFC

Truist Securities Maintains Buy on Wintrust Finl, Raises Price Target to $118

Truist Securities analyst Brandon King maintains Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) with a Buy and raises the price target from $74 to $88.

Truist Securities Maintains Buy on Western Alliance, Raises Price Target to $88

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bolt Biotherapeutics (BOLT – Research Report), Laboratory (LH – R...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bolt Biotherapeutics (BOLT), Laboratory (LH) and Biophytis (OtherBPTSY)

Biophytis (BPTSY) has released an update. Biophytis, a biotech firm targeting age-related diseases, has filed an IND application with the FDA for a...

Biophytis Targets Obesity with Phase 2 Study Filing

Biophytis (BPTSY) has released an update. Biophytis, a clinical-stage biotech company, has announced the successful scale-up of BIO101 production w...

Biophytis Advances DMD Treatment with BIO101 Scale-Up

Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Biophytis (BPTSY – Research Report). The associated price target re...

Biophytis's Strategic Growth and Positive Regulatory Momentum: Analyst Joseph Pantginis's Optimistic Outlook

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Biophytis (BPTSY – Research Report), retaining the price target of $15.00. J...

Buy Rating Affirmed: Biophytis's BIO101 Shows Promising Prospects in Obesity and Muscle Loss Treatment

BOLT

BPTSY

Biophytis

The agreement provides that Blanver will be responsible for the registration, marketing and commercialization of BIO 101 (20-Hydroxyecdysone) in its various indications: obesity, respiratory infections due to Covid-19, sarcopenia and Duchenne Muscular Dystrophy (DMD) - once Biophytis has successfully completed the planned clinical development programmes for its drug candidate. With 40 years of history, Blanver has become an expert in infectious diseases, osteoporosis and metabolic disorders, which is a perfect match with Biophytis. In addition of Brazil, Blanver has an extensive network of unique distributors that covers the whole Latin America region.

Contracts

Biophytis Announces An Exclusive License Agreement With Blanver For BIO101 (20-hydroxyecdysone) In Latin American, Biophytis Will Be Able To Receive Up To €108M Including An Upfront Payment And Further Additional Milestone Payments

BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs, together with hypocaloric dieting. The OBA phase 2 study will test the efficacy and safety of BIO101 (20-hydroxyecdysone) in patients with obesity and overweight with secondary comorbidities, who are starting treatment with GLP-1 RAs for weight loss.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Biophytis

News

Latest news for Biophytis (OTC:BPTSY) Stock

Thursday, June 20, 2024

Tuesday, May 14, 2024